Association between PAI-1 Polymorphisms and Ischemic Stroke in a South Korean Case-Control Cohort
Abstract
:1. Introduction
2. Results
2.1. Baseline Characteristics of Ischemic Stroke Patients and Controls
2.2. Genotype Frequencies of Seven PAI-1 Polymorphisms in Ischemic Stroke Patients and Controls
2.3. Genotype Frequencies of Seven PAI-1 Polymorphisms Stratified by Ischemic Stroke Subtype
2.4. Analysis of PAI-1 Haplotypes in Ischemic Stroke and Metabolic Syndrome Patients and Controls
2.5. Combined Genotype Analysis for PAI-1 in Metabolic Syndrome and Stroke Patients and Controls
2.6. Ischemic Stroke Incidence Stratified by Sex, Advanced Age, Hypertension, Diabetes Mellitus, Hyperlipidemia, Smoking, Folate, and Homocysteine
2.7. Baseline Characteristics, Genotype Frequencies and Subtypes between Ischemic Stroke Patients and Control Subjects in Subgroups 1 and 2
2.8. Clinical Variables in Ischemic Stroke Patients Stratified by PAI-1 −844GA/−675 5G Genotype
3. Discussion
4. Materials and Methods
4.1. Study Population
4.2. Determination of PAI-1 Genotypes
4.3. Statistical Analyses
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Johnson, W.; Onuma, O.; Owolabi, M.; Sachdev, S. Stroke: A global response is needed. Bull. World Health Organ. 2016, 94, 634. [Google Scholar] [CrossRef] [PubMed]
- Katan, M.; Luft, A. Global Burden of Stroke. Semin. Neurol. 2018, 38, 208–211. [Google Scholar] [CrossRef] [PubMed]
- Hong, K.S.; Bang, O.Y.; Kang, D.W.; Yu, K.H.; Bae, H.J.; Lee, J.S.; Heo, J.H.; Kwon, S.U.; Oh, C.W.; Lee, B.C.; et al. Stroke statistics in Korea: Part I. Epidemiology and risk factors: A report from the korean stroke society and clinical research center for stroke. J. Stroke 2013, 15, 2–20. [Google Scholar] [CrossRef]
- Korea National Statistical Office Web Site. The Korea National Statistical Office Report 2009: Change in Leading Causes of Death (1999–2009). Available online: http://www.kosis.kr/ups3/service/ch_file_down.jps?PUBCODE=YD&FILE_NAME=/ups3/upload/101/YD/VD0005.xls&SEQ=8 (accessed on 12 May 2022).
- Kluijtmans, L.A.; Young, I.S.; Boreham, C.A.; Murray, L.; McMaster, D.; McNulty, H.; Strain, J.J.; McPartlin, J.; Scott, J.M.; Whitehead, A.S. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood 2003, 101, 2483–2488. [Google Scholar] [CrossRef] [PubMed]
- Gellekink, H.; den Heijer, M.; Heil, S.G.; Blom, H.J. Genetic determinants of plasma total homocysteine. Semin. Vasc. Med. 2005, 5, 98–109. [Google Scholar] [CrossRef] [PubMed]
- Goldstein, L.B.; Adams, R.; Becker, K.; Furberg, C.D.; Gorelick, P.B.; Hademenos, G.; Hill, M.; Howard, G.; Howard, V.J.; Jacobs, B.; et al. Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation 2001, 103, 163–182. [Google Scholar] [CrossRef]
- Gill, J.S.; Zezulka, A.V.; Shipley, M.J.; Gill, S.K.; Beevers, D.G. Stroke and alcohol consumption. N. Engl. J. Med. 1986, 315, 1041–1046. [Google Scholar] [CrossRef]
- Sadhwani, D.; O’mara, K. Acute dissecting thoracic aortic aneurysm presenting with stroke, consumptive coagulopathy, and gastrointestinal hemorrhage. J. Emerg. Med. 1999, 17, 631–635. [Google Scholar] [CrossRef]
- Boshell, B.R. Diabetes and stroke: Coping with the consequences. Geriatrics 1981, 36, 51–65. [Google Scholar]
- Özdil, M.; Barış, S.; Özyılmaz, I.; Doğru, O.; Celkan, T.T.; Albayram, S. A rare cause of ischemic stroke: Fibromuscular dysplasia. Neurol. Sci. 2009, 30, 77–79. [Google Scholar] [CrossRef]
- Zhang, X.; Cheng, S.; Gu, H.; Jiang, Y.; Li, H.; Li, Z.; Meng, X.; Wang, Y. Family History is Related to High Risk of Recurrent Events after Ischemic Stroke or Transient Ischemic Attack. J. Stroke Cerebrovasc. Dis. 2021, 31. [Google Scholar] [CrossRef] [PubMed]
- Markaki, I.; Nilsson, U.; Kostulas, K.; Sjöstrand, C. High Cholesterol Levels Are Associated with Improved Long-term Survival after Acute Ischemic Stroke. J. Stroke Cerebrovasc. Dis. 2014, 23, e47–e53. [Google Scholar] [CrossRef] [PubMed]
- Abt, N.B.; Bydon, M.; De la Garza-Ramos, R.; McGovern, K.; Olivi, A.; Huang, J.; Bydon, A. Concurrent neoadjuvant chemotherapy is an independent risk factor of stroke, all-cause morbidity, and mortality in patients undergoing brain tumor resection. J. Clin. Neurosci. 2014, 21, 1895–1900. [Google Scholar] [CrossRef] [PubMed]
- Longstreth, W.T., Jr.; Nelson, L.M. Smoking cessation and risk of stroke in women. JAMA 1993, 269, 2214. [Google Scholar]
- Wang, J.; Yang, Y.; Zhu, J.; Shao, X.; Zhang, H.; Li, J.; Liu, L. An analysis of risk factors for stroke in atrial fibrillation and hypertension patients. Zhonghua Nei Ke Za Zhi 2014, 53. [Google Scholar]
- Jeong, W.; Joo, J.H.; Kim, H.; Jang, S.-I.; Park, E.-C. Association between statin adherence and the risk of stroke among South Korean adults with hyperlipidemia. Nutr. Metab. Cardiovasc. Dis. 2021, 32, 560–566. [Google Scholar] [CrossRef]
- Och, A.; Och, M.; Nowak, R.; Podgorska, D.; Podgorski, R. Berberine A herbal metabolite in the metabolic syndrome: The risk factors, course, and consequences of the disease. Molecules 2022, 27, 1351. [Google Scholar] [CrossRef]
- Wardlaw, J.M.; Murray, V.; Berge, E.; Del Zoppo, G.J. Thrombolysis for acute ischaemic stroke. Cochrane Datab. Syst. Rev. 2009, 2014, CD000213. [Google Scholar]
- Nagalkar, V.; Agrawal, S. Ischemic Stroke Detection Using Digital Image Processing by Fuzzy Methods. Int. J. Latest Res. Sci. Technol. 2012, 4, 345–347. [Google Scholar]
- Feigin, V.L.; Nguyen, G.; Cercy, K.; Johnson, C.O.; Alam, T.; Parmar, P.G.; Parmar, P.G.; Abajobir, A.A.; Abate, K.H.; Abd-Allah, F.; et al. Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016. N. Engl. J. Med. 2018, 379, 2429–2437. [Google Scholar]
- O’Donnell, M.J.; Chin, S.L.; Rangarajan, S.; Xavier, D.; Liu, L.; Zhang, H.; Rao-Melacini, P.; Zhang, X.; Pais, P.; Agapay, S.; et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): A case-control study. Lancet 2016, 388, 761–775. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Cai, L.; Wu, Y.; Liu, F.; Chen, Y.; Jiang, Y.; Zhou, M.; Zhu, C. The association between body mass index and risks of ischemic stroke subtypes: A Chinese cohort study. Int. J. Stroke 2019, 14, 88–95. [Google Scholar]
- Francis, C.; Marder, V. Mechanisms of fibrinolysis. In Williams Haematology, 5th ed.; McGraw Hill: New York, NY, USA, 1995. [Google Scholar]
- Schleef, R.R.; Loskutoff, D.J. Fibrinolytic system of vascular endothelial cells. Role of plasminogen activator inhibitors. Haemostasis 1988, 18, 328–341. [Google Scholar] [PubMed]
- Lijnen, H.R.; Collen, D. Mechanisms of physiological fibrinolysis. Baillieres Clin. Haematol. 1995, 8, 277–290. [Google Scholar] [CrossRef] [PubMed]
- Hoogendoorn, B.; Coleman, S.L.; Guy, C.A.; Smith, K.; Bowen, T.; Buckland, P.R.; O’Donovan, M.C. Functional analysis of human promoter polymorphisms. Hum. Mol. Genet. 2003, 12, 2249–2254. [Google Scholar] [CrossRef] [PubMed]
- Zimprich, A.; Kraus, J.; Woltje, M.; Mayer, P.; Rauch, E. An allelic variation in the human prodynorphin gene promoter alters stimulusinduced expression. J. Neurochem. 2000, 74, 472–474. [Google Scholar] [PubMed]
- Ma, Z.; Jhun, B.; Jung, S.Y.; Oh, C.K. Binding of upstream stimulatory factor 1 to the E-box regulates the 4G/5G polymorphism-dependent plasminogen activator inhibitor 1 expression in mast cells. J. Allergy Clin. Immunol. 2008, 121, 1006–1012. [Google Scholar] [CrossRef]
- Ma, Z.; Paek, D.; Oh, C.K. Plasminogen activator inhibitor-1 and asthma: Role in the pathogenesis and molecular regulation. Clin. Exp. Allergy 2009, 39, 1136–1144. [Google Scholar] [CrossRef]
- Hultman, K.; Tjarnlund-Wolf, A.; Odeberg, J.; Eriksson, P.; Jern, C. Allele-specific transcription of the PAI-1 gene in human astrocytes. Thromb. Haemost. 2010, 104, 998–1008. [Google Scholar] [CrossRef] [PubMed]
- Morange, P.E.; Saut, N.; Alessi, M.C.; Yudkin, J.S.; Margaglione, M.; Di Minno, G.; Hamsten, A.; Humphries, S.E.; Tregouet, D.A.; Juhan-Vague, I. Association of plasminogen activator inhibitor (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI-1, and metabolic parameters: The HIFMECH study. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 2250–2257. [Google Scholar] [CrossRef]
- Torres-Carrillo, N.M.; Torres-Carrillo, N.; Vazquez-Del Mercado, M.; Delgado-Rizo, V.; Oregon-Romero, E.; Parra-Rojas, I.; Muñoz-Valle, J.F. The -844 G/A PAI-1 polymorphism is associated with mRNA expression in rheumatoid arthritis. Rheumatol. Int. 2008, 28, 355–360. [Google Scholar] [CrossRef] [PubMed]
- Yende, S.; Angus, D.C.; Ding, J.; Newman, A.B.; Kellum, J.A.; Li, R.; Zmuda, J.; Kritchevsky, S.B.; Harris, T.B.; Garcia, M.; et al. 4G/5G plasminogen activator inhibitor-1 polymorphisms and haplotypes are associated with pneumonia. Am. J. Respir. Crit. Care Med. 2007, 176, 1129–1137. [Google Scholar] [CrossRef] [PubMed]
- Temprano-Sagrera, G.; Sitlani, C.M.; Bone, W.P.; Martin-Bornez, M.; Voight, B.F.; Morrison, A.C.; Damrauer, S.M.; de Vries, P.S.; Smith, N.L.; Sabater-Lleal, M. Multi-phenotype analyses of hemostatic traits with cardiovascular events reveal novel genetic associations. J. Thromb. Haemost. 2022, 20, 1331–1349. [Google Scholar] [CrossRef] [PubMed]
- Bahrami, R.; Dastgheib, S.A.; Mirjalili, H.; Setayesh, S.; Hossein, S.S.; Mirjalili, S.R.; Noorishadkam, M.; Neamatzadeh, H. Association of SERPINE1 rs1799889 polymorphism with arterial ischemic stroke in children: A systematic review and meta-analysis. Nucleosides Nucleotides Nucleic Acids 2021, 40, 1018–1035. [Google Scholar] [CrossRef] [PubMed]
- Wang, J.; Sun, Z.; Yang, Y.; Wu, J.; Quan, W.; Chen, X.; Ni, P.; Li, D. Association of laboratory parameters and genetic poly morphisms with ischemic stroke in Chinese Han population. Exp. Ther. Med. 2021, 21, 490. [Google Scholar] [CrossRef]
- Chen, C.-H.; Eng, H.-L.; Chang, C.-J.; Tsai, T.-T.; Lai, M.-L.; Chen, H.-Y.; Liu, C.-J.; Lin, T.-M. 4G/5G promoter polymorphism of plasminogen activator inhibitor-1, lipid profiles, and ischemic stroke. J. Lab. Clin. Med. 2003, 142, 100–105. [Google Scholar] [CrossRef]
- Esparza-García, J.C.; Santiago-Germán, D.; Valades-Mejía, M.G.; Hernández-Juárez, J.; Aguilar-Sosa, E.; Leaños-Miranda, A.; Alvarado-Moreno, A.; Majluf-Cruz, A.; Isordia-Salas, I. GLU298ASP and 4G/5G Polymorphisms and the Risk of Ischemic Stroke in Young Individuals. Can. J. Neurol. Sci. J. C. Sci. Neurol. 2015, 42, 310–316. [Google Scholar] [CrossRef]
- Xu, X.; Li, J.; Sheng, W.; Liu, L. Meta-analysis of genetic studies from journals published in China of ischemic stroke in the Han Chinese population. Cerebrovasc. Dis. 2008, 26, 48–62. [Google Scholar] [CrossRef]
- Barrett, L.W.; Fletcher, S.; Wilton, S.D. Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements. Cell. Mol. Life Sci. 2012, 69, 3613–3634. [Google Scholar]
- Pichon, X.; Wilson, A.; Stoneley, L.; Bastide, M.; Amandine, A.; Helen, K.; Willis, A.E. RNA Binding Protein/RNA Element Interactions and the Control of Translation. Curr. Protein Peptide Sci. 2012, 13, 294–304. [Google Scholar] [CrossRef]
- Liu, B.; Tang, Y.; Yi, M.; Liu, Q.; Xiong, H.; Hu, G.; Yuan, X. Genetic variants in the plasminogen activator inhibitor-1 gene are associated with an increased risk of radiation pneumonitis in lung cancer patients. Cancer Med. 2017, 6, 681–688. [Google Scholar] [CrossRef] [PubMed]
- Huang, X.; Li, Y.; Huang, Z.; Wang, C.; Xu, Z. Pai-1 gene variants and COC use are associated with stroke risk: A case-control study in the Han Chinese women. J. Mol. Neurosci. 2014, 54, 803–810. [Google Scholar] [CrossRef] [PubMed]
- Hoekstra, T.; Geleijnse, J.M.; Kluft, C.; Giltay, E.J.; Kok, F.J. Schouten EG. 4G/4G genotype of PAI-1 gene is associated with reduced risk of stroke in elderly. Stroke 2003, 34, 2822–2828. [Google Scholar] [CrossRef] [PubMed]
- Munoz-Valle, J.F.; Ruiz-Quezada, S.L.; Oregon-Romero, E.; Navarro-Hernandez, R.E.; Castaneda-Saucedo, E.; De la Cruz-Mosso, U.; Illades-Aguiar, B.; Leyva-Vázquez, M.A.; Castro-Alarcón, N.; Parra-Rojas, I. PAI-1 mRNA expression and plasma level in rheumatoid arthritis: Relationship with 4G/5G PAI-1 polymorphism. Rheumatol. Int. 2012, 32, 3951–3956. [Google Scholar] [CrossRef]
- Luo, Y.; Wang, C.; Tu, H. Impact of the 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene on primary nephrotic syndrome. Mol. Med. Rep. 2014, 9, 894–898. [Google Scholar] [CrossRef]
- Corre, S.; Galibert, M.D. Upstream stimulating factors: Highly versatile stress responsive transcription factors. Pigment Cell Res. Oct. 2005, 18, 337–348. [Google Scholar] [CrossRef]
- Adamski, M.G.; Turaj, W.; Slowik, A.; Wloch-Kopec, D.; Wolkow, P.; Szczudlik, A. A-G-4G haplotype of PAI-1 gene polymorphisms -844 G/A, HindIII G/C, and -675 4G/5G is associated with increased risk of ischemic stroke caused by small vessel disease. Acta Neurol. Scand. 2009, 120, 94–100. [Google Scholar] [CrossRef]
- Wang, Y.; Long, J.; Wang, X.; Sun, Y. Association of the plasminogen activator inhibitor-1 (PAI-1) Gene -675 4G/5G and -844 A/G promoter polymorphism with risk of keloid in a Chinese Han population. Med. Sci. Monit. 2014, 20, 2069–2073. [Google Scholar]
- Torrente, D.; Su, E.J.; Fredriksson, L.; Warnock, M.; Bushart, D.; Mann, K.M.; Emal, C.D.; Lawrence, D.A. Compartmentalized actions of the plasminogen activator inhibitors, PAI-1 and nsp, in ischemic stroke. Transl. Stroke Res. 2022, 13, 801–815. [Google Scholar] [CrossRef]
- Sales, M.F.; Soter, M.O.; Candido, A.L.; Fernandes, A.P.; Oliveira, F.R.; Ferreira, A.C.; Sousa, M.O.; Ferreira, C.N.; Gomes, K.B. Correlation between plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G polymorphism and metabolic/proinflammatory factors in polycystic ovary syndrome. Gynecol. Endocrinol. 2013, 29, 936–939. [Google Scholar] [CrossRef]
- Roncal, C.; Orbe, J.; Rodriguez, J.A.; Paramo, J.A. 4G/5G polymorphisms of PAI-1 in the metabolic syndrome. Med. Clin. 2006, 126, 234. [Google Scholar] [CrossRef] [PubMed]
- Gao, Y.; Jin, H. Livedoid vasculopathy and its association with genetic variants: A systematic review. Int. Wound J. 2021, 18, 616–625. [Google Scholar] [CrossRef] [PubMed]
- Di Mascio, R.; Marchioli, R.; Vitullo, F.; Di Pasquale, A.; Cavasinni, L.; Tognoni, G. Serum cholesterol and risk of ischemic stroke: Results of a case-control study. On behalf of PROGETTO 3A Investigators. Prev. Med. 1995, 24, 128–133. [Google Scholar] [CrossRef] [PubMed]
- Huang, G.; Xu, J.; Zhang, Z.; Cai, L.; Liu, H.; Yu, X. Total cholesterol and high density lipoprotein cholesterol ratio is associated with metabolic syndrome in a very elderly Chinese population. Sci. Rep. 2022, 12, 1–8. [Google Scholar] [CrossRef]
- Li, H.; Qian, F.; Zuo, Y.; Yuan, J.; Chen, S.; Wu, S.; Wang, A. U-Shaped Relationship of High-Density Lipoprotein Cholesterol and Incidence of Total, Ischemic and Hemorrhagic Stroke: A Prospective Cohort Study. Stroke 2022, 53, 1624–1632. [Google Scholar] [CrossRef]
- Liang, H.; Zhang, Q.; Hu, Y.; Liu, G.; Qi, R. Hypertriglyceridemia: A neglected risk factor for ischemic stroke? J. Stroke 2022, 24, 21–40. [Google Scholar] [CrossRef]
- Kim, J.O.; Han, S.H.; Lee, Y.H.; Ahn, T.K.; Lim, J.J.; Chung, Y.S.; Lee, W.S.; Han, I.B.; Kim, N.K. Association of Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms with Osteoporotic Vertebral Compression Fractures (OVCFs) in Postmenopausal Women. Int. J. Mol. Sci. 2016, 17, 2062. [Google Scholar] [CrossRef]
- Oh, J.; An, H.J.; Kim, J.O.; Jun, H.H.; Kim, W.R.; Kim, E.J.; Oh, D.; Kim, J.W.; Kim, N.K. Association between Five Common Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms and Colorectal Cancer Susceptibility. Int. J. Mol. Sci. 2020, 21, 4334. [Google Scholar] [CrossRef]
- Park, H.S.; Sung, J.H.; Ryu, C.S.; Lee, J.Y.; Ko, E.J.; Kim, I.J.; Kim, N.K. The Synergistic Effect of Plasminogen Activator Inhibitor-1 (PAI-1) Polymorphisms and Metabolic Syndrome on Coronary Artery Disease in the Korean Population. J. Pers. Med. 2020, 10, 257. [Google Scholar] [CrossRef]
- Mendell, J.T. MicroRNAs: Critical regulators of development, cellular physiology and malignancy. Cell Cycle 2005, 4, 1179–1184. [Google Scholar] [CrossRef]
- Lee, H.S.; Lee, S.H. Importance of genetic polymorphisms in stroke: An update. J. Stroke 2015, 17, 221–230. [Google Scholar] [CrossRef] [PubMed]
- Dehghan, A.; Kottgen, A. Genome-wide association studies and Mendelian randomization analyses for leisure sedentary behaviours. Nat. Rev. Endocrinol. 2008, 14, 697–705. [Google Scholar]
- Chen, H.; Wu, B.; Fan, L.; Wang, J. Polymorphisms of the PAI-1 gene and ischemic stroke: A meta-analysis. J. Stroke Cerebrovasc. Dis. 2020, 29, 104635. [Google Scholar]
- Li, Z.; Li, Y.; Chen, J.; Li, S.; Xu, H.; Li, Y. Polymorphisms of the PAI-1 gene and stroke: A systematic review and meta-analysis. Neurosci. Lett. 2020, 716, 134688. [Google Scholar]
- Kim, H.; Cho, C.; Cho, Y.; Cho, S.; Yoon, K.; Kim, K. Significant associations of PAI-1 genetic polymorphisms with osteonecrosis of the femoral head. BMC Musculoskelet. Disord. 2011, 14, 160. [Google Scholar] [CrossRef]
- Jeon, Y.J.; Kim, Y.R.; Lee, B.E.; Choi, Y.S.; Kim, J.H.; Shin, J.E.; Rah, H.; Cha, S.H.; Lee, W.S.; Kim, N.K. Genetic association of five plasminogen activator inhibitor-1 (PAI-1) polymorphisms and idiopathic recurrent pregnancy loss in Korean women. Thromb. Haemost. 2013, 110, 742–750. [Google Scholar]
- Jafari, M.; Jarahzadeh, M.H.; Dastgheib, S.A.; Shalamzari, N.S.; Ezzabadi, A.R.; Sadeghizadeh-Yazdi, J.; Akbarian, E.; Neamatzadeh, H. Association of PAI-1 rs1799889 Polymorphism with Susceptibility to Ischemic Stroke: A Huge Meta-Analysis based on 44 Studies. Acta Med. 2020, 63, 31–42. [Google Scholar] [CrossRef]
- Liua, Y.; Chenga, J.; Guoa, X.; Moa, J.; Gaoa, Y.B.; Zhou, H.; Wu, Y.; Li, Z. The roles of PAI-1 gene polymorphisms in atherosclerotic diseases: A systematic review and meta-analysis involving 149,908 subjects. Gene 2018, 673, 167–173. [Google Scholar] [CrossRef]
- Hu, X.; Zan, X.; Xie, Z.; Li, Y.; Lin, S.; Li, H.; You, C. Association Between Plasminogen Activator Inhibitor-1 Genetic Polymorphisms and Stroke Susceptibility. Mol. Neurobiol. 2017, 54, 328–341. [Google Scholar] [CrossRef]
- Kang, L.; Zou, X.; Zhang, G.; Xiang, J.; Wang, Y.; Yang, M.; Chen, X.; Wu, J.; Guan, H. A variant in a microRNA binding site in NEIL2 3’UTR confers susceptibility to age-related cataracts. FASEB J. 2019, 33, 10469–10476. [Google Scholar] [CrossRef] [PubMed]
- Marchand, A.; Proust, C.; Morange, P.E.; Lompre, A.M.; Tregouet, D.A. miR-421 and miR-30c inhibit SERPINE 1 gene expression in human endothelial cells. PLoS ONE 2012, 7, e44532. [Google Scholar] [CrossRef] [PubMed]
- Lee, B.C.; Roh, J.K. International experience in stroke registries: Korean Stroke Registry. Am. J. Prev. Med. 2006, 31, S243–S245. [Google Scholar] [CrossRef] [PubMed]
Characteristic | Controls (n = 425) | Stroke Patients (n = 574) | p a |
---|---|---|---|
Male (%) | 173 (40.7) | 234 (40.8) | 1.000 |
Age (years, mean ± SD) | 62.62 ± 10.77 | 62.63 ± 11.56 | 0.986 |
Smoking (%) | 138 (32.5) | 206 (35.9) | 0.448 |
Metabolic syndrome (%) | 48 (11.3) | 187 (32.6) | <0.0001 |
Hypertension (%) | 170 (40.0) | 362 (63.1) | <0.0001 |
Diabetes mellitus (%) | 56 (13.2) | 146 (25.4) | <0.0001 |
Hyperlipidemia (%) | 101 (23.8) | 181 (31.5) | 0.047 |
BMI (kg/m2, mean ± SD) | 24.23 ± 3.24 | 24.15 ± 3.09 | 0.723 |
HDL-C (mg/dl, mean ± SD) | 46.40 ± 12.71 | 44.81 ± 14.26 | 0.042 |
Homocysteine (μmol/L, mean ± SD) | 9.96 ± 4.10 | 11.14 ± 6.73 | 0.001 |
Folate (nmol/L, mean ± SD) | 8.88 ± 7.88 | 7.01 ± 5.19 | <0.0001 |
Vitamin B12 (pg/mL, mean ± SD) | 742.81 ± 666.61 | 739.84 ± 618.84 | 0.943 |
Total cholesterol (mg/dL, mean ± SD) | 194.03 ± 37.81 | 191.41 ± 40.25 | 0.301 |
Triglyceride (mg/dL, mean ±SD) | 145.97 ± 88.82 | 151.56 ± 101.30 | 0.369 |
PLT (103/μL, mean ± SD) | 243.00 ± 66.59 | 249.55 ± 87.81 | 0.202 |
PT (s, mean ± SD) | 11.76 ± 0.81 | 11.79 ± 0.98 | 0.720 |
aPTT (s, mean ± SD) | 33.36 ± 18.28 | 30.44 ± 4.43 | 0.0004 |
Fibrinogen (mg/dL, mean ± SD) | 393.29 ± 119.56 | 422.22 ± 129.11 | 0.016 |
Antithrombin (%, mean ± SD) | 94.31 ± 43.40 | 94.28 ± 18.69 | 0.990 |
BUN (mg/dL, mean ± SD) | 15.85 ± 4.98 | 16.00 ± 7.35 | 0.706 |
Uric acid (mg/dL, mean ± SD) | 4.63 ± 1.44 | 4.66 ± 1.57 | 0.735 |
Characteristics | Controls (n = 425) | Stroke Patients (n = 574) | COR (95% CI) | p | FDR-P | AOR (95% CI) a | p | FDR-P |
---|---|---|---|---|---|---|---|---|
PAI-1 −844[rs2227631]G>A | ||||||||
GG | 162 (38.1) | 201 (35.0) | 1.000 (reference) | 1.000 (reference) | ||||
GA | 191 (44.9) | 292 (50.9) | 1.232 (0.935–1.624) | 0.138 | 0.327 | 1.122 (0.840–1.499) | 0.436 | 0.610 |
AA | 72 (16.9) | 81 (14.1) | 0.907 (0.621–1.325) | 0.613 | 0.715 | 0.940 (0.630–1.402) | 0.762 | 0.762 |
Dominant | 1.143 (0.881–1.483) | 0.314 | 0.366 | 1.077 (0.820–1.414) | 0.595 | 0.694 | ||
Recessive | 0.806 (0.570–1.138) | 0.220 | 0.384 | 0.867 (0.604–1.244) | 0.438 | 0.526 | ||
HWE P | 0.224 | 0.126 | ||||||
PAI-1 −675[rs1799889]4G>5G | ||||||||
4G4G | 182 (42.8) | 214 (37.3) | 1.000 (reference) | 1.000 (reference) | ||||
4G5G | 188 (44.2) | 258 (44.9) | 1.119 (0.852–1.470) | 0.419 | 0.489 | 1.093 (0.821–1.455) | 0.543 | 0.634 |
5G5G | 55 (12.9) | 102 (17.8) | 1.579 (1.078–2.312) | 0.019 | 0.067 | 1.646 (1.095–2.473) | 0.017 | 0.051 |
Dominant | 1.223 (0.947–1.579) | 0.123 | 0.179 | 1.197 (0.916–1.564) | 0.189 | 0.331 | ||
Recessive | 1.489 (1.045–2.121) | 0.028 | 0.098 | 1.513 (1.045–2.189) | 0.028 | 0.087 | ||
HWE P | 0.378 | 0.117 | ||||||
PAI-1 43[rs6092]G>A | ||||||||
GG | 348 (81.9) | 491 (85.5) | 1.000 (reference) | 1.000 (reference) | ||||
GA | 70 (16.5) | 78 (13.6) | 0.790 (0.556–1.122) | 0.187 | 0.327 | 0.831 (0.575–1.202) | 0.326 | 0.571 |
AA | 7 (1.6) | 5 (0.9) | 0.506 (0.159–1.608) | 0.248 | 0.434 | 0.552 (0.166–1.835) | 0.332 | 0.498 |
Dominant | 0.764 (0.544–1.073) | 0.120 | 0.179 | 0.809 (0.566–1.155) | 0.243 | 0.340 | ||
Recessive | 0.525 (0.165–1.665) | 0.274 | 0.384 | 0.572 (0.172–1.906) | 0.363 | 0.526 | ||
HWE P | 0.121 | 0.337 | ||||||
PAI-1 9785[rs2227694] A>G | ||||||||
GG | 396 (93.2) | 531 (92.5) | 1.000 (reference) | 1.000 (reference) | ||||
GA | 28 (6.6) | 42 (7.3) | 1.119 (0.682–1.836) | 0.658 | 0.658 | 1.064 (0.634–1.783) | 0.815 | 0.815 |
AA | 1 (0.2) | 1 (0.2) | 0.746 (0.047–11.960) | 0.836 | 0.836 | N/A | 0.993 | N/A |
Dominant | 1.106 (0.678–1.803) | 0.687 | 0.687 | 1.022 (0.613–1.704) | 0.934 | 0.934 | ||
Recessive | 0.740 (0.046–11.865) | 0.832 | 0.832 | N/A | 0.993 | N/A | ||
HWE P | 0.503 | 0.859 | ||||||
PAI-1 10692[rs11178]T>C | ||||||||
TT | 159 (37.4) | 185 (32.2) | 1.000 (reference) | 1.000 (reference) | ||||
TC | 204 (48.0) | 287 (50.0) | 1.209 (0.916–1.596) | 0.180 | 0.327 | 1.311 (0.979–1.755) | 0.069 | 0.242 |
CC | 62 (14.6) | 102 (17.8) | 1.414 (0.967–2.068) | 0.074 | 0.173 | 1.504 (1.003–2.255) | 0.048 | 0.096 |
Dominant | 1.257 (0.966–1.635) | 0.089 | 0.179 | 1.348 (1.022–1.777) | 0.034 | 0.119 | ||
Recessive | 1.265 (0.897–1.785) | 0.180 | 0.384 | 1.264 (0.882–1.812) | 0.202 | 0.404 | ||
HWE P | 0.793 | 0.609 | ||||||
PAI-1 11053[rs7242]T>G | ||||||||
TT | 108 (25.4) | 166 (28.9) | 1.000 (reference) | 1.000 (reference) | ||||
TG | 217 (51.1) | 267 (46.5) | 0.754 (0.558–1.019) | 0.066 | 0.327 | 0.783 (0.573–1.071) | 0.126 | 0.294 |
GG | 100 (23.5) | 141 (24.6) | 0.910 (0.640–1.292) | 0.596 | 0.715 | 0.885 (0.611–1.281) | 0.517 | 0.620 |
Dominant | 0.803 (0.605–1.065) | 0.128 | 0.179 | 0.820 (0.610–1.101) | 0.187 | 0.331 | ||
Recessive | 1.088 (0.812–1.459) | 0.571 | 0.666 | 1.048 (0.771–1.423) | 0.766 | 0.766 | ||
HWE P | 0.657 | 0.104 | ||||||
PAI-1 12068[rs1050955] G>A | ||||||||
GG | 163 (38.4) | 190 (33.1) | 1.000 (reference) | 1.000 (reference) | ||||
GA | 210 (49.4) | 283 (49.3) | 1.156 (0.878–1.522) | 0.301 | 0.421 | 1.330 (0.993–1.783) | 0.056 | 0.242 |
AA | 52 (12.2) | 101 (17.6) | 1.666 (1.123–2.472) | 0.011 | 0.067 | 1.784 (1.177–2.704) | 0.006 | 0.036 |
Dominant | 1.257 (0.968–1.633) | 0.086 | 0.179 | 1.421 (1.078–1.875) | 0.013 | 0.091 | ||
Recessive | 1.532 (1.068–2.198) | 0.021 | 0.098 | 1.520 (1.043–2.216) | 0.029 | 0.087 | ||
HWE P | 0.212 | 0.804 |
Characteristics | Controls (n = 425) | LAD (n = 200) | AOR (95% CI)a | p | FDR-P | SVD (n = 140) | AOR (95% CI) a | p | FDR-P | CE (n = 52) | AOR (95% CI) a | p | FDR-P |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PAI-1 −675 [rs1799889]4G>5G | |||||||||||||
4G4G | 182 (42.8) | 74 (37.0) | 1.000 (reference) | 55 (39.3) | 1.000 (reference) | 17 (32.7) | 1.000 (reference) | ||||||
4G5G | 188 (44.2) | 92 (46.0) | 1.167 (0.790–1.725) | 0.437 | 0.653 | 59 (42.1) | 0.937 (0.602–1.458) | 0.772 | 0.901 | 21 (40.4) | 1.208 (0.610–2.391) | 0.588 | 0.735 |
5G5G | 55 (12.9) | 34 (17.0) | 1.652 (0.937–2.914) | 0.083 | 0.212 | 26 (18.6) | 1.697 (0.930–3.098) | 0.085 | 0.142 | 14 (26.9) | 2.790 (1.239–6.279) | 0.013 | 0.065 |
Dominant | 1.240 (0.859–1.790) | 0.251 | 0.407 | 1.069 (0.709–1.610) | 0.751 | 0.860 | 1.566 (0.843–2.909) | 0.155 | 0.813 | ||||
Recessive | 1.426 (0.870–2.338) | 0.160 | 0.458 | 1.628 (0.951–2.788) | 0.076 | 0.190 | 2.529 (1.254–5.099) | 0.010 | 0.050 | ||||
PAI-1 10692 [rs11178]T>C | |||||||||||||
TT | 159 (37.4) | 63 (31.5) | 1.000 (reference) | 39 (27.9) | 1.000 (reference) | 17 (32.7) | 1.000 (reference) | ||||||
TC | 204 (48.0) | 105 (52.5) | 1.446 (0.970–2.155) | 0.070 | 0.245 | 71 (50.7) | 1.500 (0.943–2.386) | 0.087 | 0.235 | 28 (53.8) | 1.237 (0.646–2.369) | 0.520 | 0.735 |
CC | 62 (14.6) | 32 (16.0) | 1.543 (0.866–2.751) | 0.141 | 0.212 | 30 (21.4) | 2.238 (1.225–4.087) | 0.009 | 0.045 | 7 (13.5) | 1.152 (0.449–2.956) | 0.769 | 0.869 |
Dominant | 1.439 (0.982–2.109) | 0.062 | 0.217 | 1.646 (1.061–2.553) | 0.026 | 0.154 | 1.194 (0.642–2.219) | 0.575 | 0.813 | ||||
Recessive | 1.115 (0.681–1.828) | 0.665 | 0.798 | 1.694 (1.015–2.826) | 0.044 | 0.190 | 0.925 (0.394–2.169) | 0.857 | 0.912 | ||||
PAI-1 12068 [rs1050955] G>A | |||||||||||||
GG | 163 (38.4) | 61 (30.5) | 1.000 (reference) | 44 (31.4) | 1.000 (reference) | 18 (34.6) | 1.000 (reference) | ||||||
GA | 210 (49.4) | 107 (53.5) | 1.793 (1.187–2.707) | 0.006 | 0.042 | 72 (51.4) | 1.416 (0.898–2.233) | 0.134 | 0.235 | 25 (48.1) | 1.133 (0.588–2.184) | 0.710 | 0.735 |
AA | 52 (12.2) | 32 (16.0) | 1.946 (1.080–3.505) | 0.027 | 0.162 | 24 (17.1) | 1.795 (0.965–3.341) | 0.065 | 0.142 | 9 (17.3) | 1.647 (0.687–3.950) | 0.263 | 0.658 |
Dominant | 1.792 (1.212–2.648) | 0.003 | 0.021 | 1.509 (0.982–2.319) | 0.060 | 0.154 | 1.242 (0.672–2.296) | 0.489 | 0.813 | ||||
Recessive | 1.314 (0.791–2.183) | 0.292 | 0.458 | 1.472 (0.845–2.566) | 0.173 | 0.288 | 1.505 (0.685–3.306) | 0.309 | 0.773 |
Characteristic | Stroke Controls (2n = 850) | Stroke Patients (2n = 1148) | OR (95% CI) | p a | FDR-P |
---|---|---|---|---|---|
PAI-1 −844G>A/−675 4G>5G/43G>A/9785G>A/10692T>C/11053T>G/12068G>A | |||||
G-4G-G-G-T-T-G | 18 (2.1) | 16 (1.4) | 1.000 (reference) | ||
A-4G-A-G-T-G-G | 22 (2.6) | 3 (0.3) | 0.153 (0.039–0.611) | 0.005 | 0.075 |
A-5G-G-G-C-T-A | 0 (0.0) | 37 (3.2) | 84.090 (4.774–1481.000) | <0.0001 | 0.003 |
PAI-1 −844G>A/−675 4G>5G/43G>A/10692T>C/11053T>G/12068G>A | |||||
G-4G-G-T-T-G | 21 (2.5) | 19 (1.7) | 1.000 (reference) | ||
G-4G-G-T-G-G | 77 (9.0) | 158 (13.8) | 2.268 (1.151–4.467) | 0.020 | 0.107 |
G-5G-A-C-T-A | 23 (2.7) | 48 (4.2) | 2.307 (1.041–5.109) | 0.045 | 0.181 |
A-4G-A-T-G-G | 23 (2.7) | 4 (0.3) | 0.192 (0.056–0.658) | 0.008 | 0.096 |
A-5G-G-C-T-A | 0 (0.0) | 39 (3.4) | 87.100 (5.005–1516.000) | <0.0001 | 0.003 |
PAI-1 −844G>A/−675 4G>5G/10692T>C/11053T>G/12068G>A | |||||
G-4G-T-T-G | 29 (3.4) | 20 (1.8) | 1.000 (reference) | ||
G-4G-T-G-G | 87 (10.2) | 155 (13.5) | 2.583 (1.379–4.838) | 0.004 | 0.031 |
G-4G-T-G-A | 3 (0.4) | 12 (1.0) | 5.800 (1.448–23.240) | 0.016 | 0.065 |
G-5G-C-T-A | 158 (18.6) | 217 (18.9) | 1.991 (1.087–3.649) | 0.032 | 0.105 |
A-4G-T-T-A | 5 (0.6) | 12 (1.1) | 3.480 (1.060–11.430) | 0.049 | 0.12 |
A-4G-C-T-A | 17 (2.1) | 35 (3.1) | 2.985 (1.324–6.729) | 0.010 | 0.058 |
A-5G-T-G-G | 1 (0.2) | 12 (1.0) | 17.400 (2.092–144.800) | 0.001 | 0.012 |
A-5G-C-T-A | 0 (0.0) | 43 (3.8) | 125.200 (7.280–2153.000) | <0.0001 | 0.002 |
PAI-1 −844G>A/−675 4G>5G/43G>A/10692T>C | |||||
G-4G-G-T | 112 (13.2) | 198 (17.2) | 1.000 (reference) | ||
G-4G-G-C | 82 (9.6) | 94 (8.2) | 0.648 (0.445–0.945) | 0.027 | 0.056 |
G-4G-A-T | 15 (1.7) | 4 (0.3) | 0.151 (0.049–0.466) | 0.0003 | 0.002 |
G-4G-A-C | 11 (1.3) | 6 (0.5) | 0.309 (0.111–0.857) | 0.022 | 0.056 |
G-5G-G-T | 77 (9.1) | 86 (7.5) | 0.632 (0.430–0.929) | 0.023 | 0.056 |
A-4G-G-T | 281 (33.1) | 331 (28.8) | 0.666 (0.503–0.883) | 0.005 | 0.019 |
A-4G-A-T | 28 (3.3) | 7 (0.6) | 0.141 (0.060–0.334) | <0.0001 | 0.001 |
A-5G-G-C | 0 (0.0) | 40 (3.5) | 45.910 (2.794–754.300) | <0.0001 | 0.001 |
PAI-1 −844G>A/−675 4G>5G/10692T>C | |||||
G-4G-T | 127 (15.0) | 201 (17.6) | 1.000 (reference) | ||
A-4G-T | 309 (36.4) | 339 (29.5) | 0.693 (0.529–0.909) | 0.008 | 0.028 |
A-5G-T | 3 (0.3) | 19 (1.6) | 4.002 (1.160–13.800) | 0.021 | 0.049 |
A-5G-C | 0 (0.0) | 49 (4.3) | 62.640 (3.827–1025.000) | <0.0001 | 0.0007 |
PAI-1 −844G>A/−675 4G>5G | |||||
G-4G | 220 (25.9) | 304 (26.5) | 1.000 (reference) | ||
A-5G | 3 (0.3) | 70 (6.1) | 16.890 (5.247–54.340) | <0.0001 | 0.0003 |
Genotype | MetS | MetS | OR (95% CI) | p | FDR-P | Stroke | Stroke | AOR (95% CI) | p a,b | FDR-P | |
---|---|---|---|---|---|---|---|---|---|---|---|
Controls | Patients | Controls | Patients | ||||||||
(n = 764) | (n = 235) | (n = 425) | (n = 574) | ||||||||
PAI-1 −844G>A/−675 4G>5G (rs2227631/rs1799889) | |||||||||||
GG-4G4G | 63 (8.2) | 14 (6.0) | 1.000 (reference) | 38 (8.9) | 39 (6.8) | 1.000 (reference) | |||||
GA-5G5G | 12 (1.6) | 8 (3.4) | 3.000 (1.034–8.709) | 0.043 | 0.172 | 2 (0.5) | 18 (3.1) | 8.389 (1.671–42.110) | 0.01 | 0.030 | |
PAI-1 −844G>A/10692T> C (rs2227631/rs11178) | |||||||||||
GG-TT | 70 (9.2) | 21 (8.9) | 1.000 (reference) | 37 (8.7) | 54 (9.4) | 1.000 (reference) | |||||
GA-CC | 17 (2.2) | 9 (3.8) | 1.765 (0.687–4.535) | 0.238 | 0.476 | 4 (0.9) | 22 (3.8) | 4.035 (1.145–14.217) | 0.03 | 0.030 | |
AA-TT | 79 (10.3) | 21 (8.9) | 0.886 (0.447–1.758) | 0.729 | 0.933 | 58 (13.6) | 42 (7.3) | 0.455 (0.238–0.872) | 0.018 | 0.030 | |
AA-TC | 38 (5.0) | 11 (4.7) | 0.965 (0.421–2.212) | 0.933 | 0.933 | 14 (3.3) | 35 (6.1) | 2.659 (1.126–6.276) | 0.026 | 0.030 | |
PAI-1 −844G>A/11053T>G (rs2227631/rs7242) | |||||||||||
GG-TT | 147 (19.2) | 41 (17.4) | 1.000 (reference) | 83 (19.5) | 105 (18.3) | 1.000 (reference) | |||||
AA-TT | 9 (1.2) | 5 (2.1) | 1.992 (0.633–6.270) | 0.239 | 0.432 | 1 (0.2) | 13 (2.3) | 10.968 (1.351–89.059) | 0.025 | 0.030 | |
PAI-1 −675 4G>5G/43G>A (rs1799889/rs6092) | |||||||||||
4G4G-GG | 258 (33.8) | 94 (40.0) | 1.000 (reference) | 144 (33.9) | 208 (36.2) | 1.000 (reference) | |||||
4G4G-GA | 44 (5.8) | 2 (0.9) | 0.125 (0.030–0.525) | 0.005 | 0.005 | 37 (8.7) | 9 (1.6) | 0.194 (0.088–0.428) | 0.0001 | 0.0006 | |
PAI-1 −675 4G>5G/10692T>C (rs1799889/rs11178) | |||||||||||
4G4G-TT | 174 (22.8) | 64 (27.2) | 1.000 (reference) | 109 (25.6) | 129 (22.5) | 1.000 (reference) | |||||
5G5G-TC | 43 (5.6) | 11 (4.7) | 0.696 (0.338–1.431) | 0.324 | 0.432 | 18 (4.2) | 36 (6.3) | 1.983 (1.011–3.891) | 0.047 | 0.049 | |
5G5G-CC | 65 (8.5) | 21 (8.9) | 0.878 (0.497–1.552) | 0.655 | 0.655 | 29 (6.8) | 57 (9.9) | 1.803 (1.030–3.154) | 0.039 | 0.049 | |
PAI-1 −675 4G>5G/12068G>A (rs1799889/rs1050955) | |||||||||||
4G4G-GG | 162 (21.2) | 61 (26.0) | 1.000 (reference) | 101 (23.8) | 122 (21.3) | 1.000 (reference) | |||||
5G5G-AA | 47 (6.2) | 14 (6.0) | 0.791 (0.407–1.539) | 0.490 | 0.490 | 20 (4.7) | 41 (7.1) | 1.908 (1.002–3.631) | 0.049 | 0.049 | |
PAI-1 43G>A/10692T>C (rs6092/rs11178) | |||||||||||
GG-TT | 219 (28.7) | 85 (36.2) | 1.000 (reference) | 130 (30.6) | 174 (30.3) | 1.000 (reference) | |||||
GA-TT | 32 (4.2) | 7 (3.0) | 0.564 (0.240–1.326) | 0.189 | 0.252 | 29 (6.8) | 10 (1.7) | 0.269 (0.120–0.604) | 0.001 | 0.004 | |
PAI-1 43G>A/11053T>G (rs6092/rs7242) | |||||||||||
GG-TT | 166 (21.7) | 53 (22.6) | 1.000 (reference) | 87 (20.5) | 132 (23.0) | 1.000 (reference) | |||||
GA-GG | 20 (2.6) | 1 (0.4) | 0.157 (0.021–1.195) | 0.074 | 0.232 | 16 (3.8) | 5 (0.9) | 0.247 (0.085–0.712) | 0.01 | 0.015 | |
PAI-1 43G>A/12068G>A (rs6092/rs1050955) | |||||||||||
GG-GG | 232 (30.4) | 82 (34.9) | 1.000 (reference) | 134 (31.5) | 180 (31.4) | 1.000 (reference) | |||||
GA-GG | 31 (4.1) | 5 (2.1) | 0.456 (0.172–1.213) | 0.116 | 0.232 | 28 (6.6) | 8 (1.4) | 0.215 (0.092–0.502) | 0.0003 | 0.0009 | |
GA-AA | 20 (2.6) | 9 (3.8) | 1.273 (0.557–2.908) | 0.567 | 0.567 | 6 (1.4) | 23 (4.0) | 3.184 (1.195–8.483) | 0.021 | 0.021 | |
PAI-1 9785G>A/12068G>A (rs2227694/rs1050955) | |||||||||||
GG-GG | 237 (31.0) | 78 (33.2) | 1.000 (reference) | 151 (35.5) | 164 (28.6) | 1.000 (reference) | |||||
GG-GA | 357 (46.7) | 104 (44.3) | 0.885 (0.632–1.239) | 0.477 | 0.636 | 195 (45.9) | 266 (46.3) | 1.415 (1.041–1.923) | 0.027 | 0.035 | |
GG-AA | 114 (14.9) | 37 (15.7) | 0.986 (0.629–1.548) | 0.952 | 0.952 | 50 (11.8) | 101 (17.6) | 1.944 (1.270–2.974) | 0.002 | 0.008 | |
PAI-1 10692T>C/12068G>A (rs11178/rs1050955) | |||||||||||
TC-GA | 283 (37.0) | 79 (33.6) | 0.787 (0.540–1.145) | 0.211 | 0.636 | 150 (35.3) | 212 (36.9) | 1.485 (1.051–2.098) | 0.025 | 0.035 | |
CC-AA | 81 (10.6) | 23 (9.8) | 0.800 (0.466–1.375) | 0.420 | 0.636 | 38 (8.9) | 66 (11.5) | 1.707 (1.039–2.804) | 0.035 | 0.035 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Choi, G.H.; Cho, S.H.; An, H.J.; Park, H.S.; Lee, J.Y.; Ko, E.J.; Oh, S.H.; Kim, O.J.; Kim, N.K. Association between PAI-1 Polymorphisms and Ischemic Stroke in a South Korean Case-Control Cohort. Int. J. Mol. Sci. 2023, 24, 8041. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms24098041
Choi GH, Cho SH, An HJ, Park HS, Lee JY, Ko EJ, Oh SH, Kim OJ, Kim NK. Association between PAI-1 Polymorphisms and Ischemic Stroke in a South Korean Case-Control Cohort. International Journal of Molecular Sciences. 2023; 24(9):8041. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms24098041
Chicago/Turabian StyleChoi, Gun Ho, Sung Hwan Cho, Hui Jeong An, Han Sung Park, Jeong Yong Lee, Eun Ju Ko, Seung Hun Oh, Ok Joon Kim, and Nam Keun Kim. 2023. "Association between PAI-1 Polymorphisms and Ischemic Stroke in a South Korean Case-Control Cohort" International Journal of Molecular Sciences 24, no. 9: 8041. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms24098041